Kalimat Medical Center Ltd.

Sofia 22 trials 9 recruiting

22 Registered trials

9 Currently recruiting

Organisation

Kalimat Medical Center Ltd.

Location

Sofia, Bulgaria

Identifier

ORG-100044606

Address

Ulitsa Yastrebets 11, 1680, Bulgaria

Departments

-
Cardiology office
Consulting room of Cardiology
N/A
NA
Nephrology office
Not Applicable

Clinical trials at this site (22)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting

2023-503545-67-00 Tourette's Disorder 5 2024-04-30
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with … Recruiting

2025-522407-23-00 Chronic kidney disease (CKD) and hypertension. 4 2026-04-16
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended

2023-509709-63-00 Chronic Kidney Disease and Albuminuria 4 2024-07-30
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended

2023-503494-38-00 Tourette’s Disorder 5 2023-07-20
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Insomnia Disorder 4 2022-12-05
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended

2024-510696-38-00 Severe Hypertriglyceridemia. 5 2022-03-08
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24